Biocon Secures Global Patent Settlement with Genentech for Pebrilzo Biosimilar, Targets European Launch in 2027

Indian biopharmaceutical company Biocon Limited has secured a global patent settlement and licensing agreement with Genentech, establishing a pathway for the international commercialisation of Pebrilzo, its biosimilar version of the breast cancer medicine Perjeta (pertuzumab). The agreement resolves pending patent disputes between the companies and establishes permitted launch timelines across major pharmaceutical markets, including Europe, the United Kingdom, the United States and Canada.

In an official announcement to stock exchanges on October 14, 2026, Bengaluru-headquartered Biocon confirmed that the agreement enables the company to launch Pebrilzo in the European Union and United Kingdom during the first quarter of calendar year 2027, followed by the United States in the third quarter of 2028. Launches in other international markets are covered by arrangements spanning 2026 to 2028, with earlier entry possible in certain circumstances.

The agreement represents a significant development for Biocon’s oncology biosimilars portfolio and its efforts to expand access to advanced biological medicines across international markets.

Pebrilzo contains pertuzumab, a monoclonal antibody used in the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. It is being developed as a biosimilar to Genentech’s reference medicine, Perjeta.

The patent settlement follows another important development in September 2026, when the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorisation for Pebrilzo.

Together, the regulatory progress and patent licensing agreement establish an important foundation for Biocon’s planned introduction of the medicine across international oncology markets.

Biocon and Genentech Resolve Global Patent Disputes

Biocon’s October 14 announcement confirmed that the company had executed a global settlement and licence agreement with Genentech, resolving pending disputes concerning its pertuzumab biosimilar.

The agreement covers disputes in the United States, Canada and other jurisdictions, establishing a licensing framework for Pebrilzo’s commercial introduction.Genentech is the developer of the reference medicine Perjeta, which contains pertuzumab and is used in certain treatment regimens for HER2-positive breast cancer.

Patents covering innovative biological medicines form an important part of the pharmaceutical industry because they protect inventions associated with the development of complex therapeutic products.For biosimilar manufacturers, patent settlements can provide greater clarity regarding the timing of market entry while avoiding prolonged litigation.

Biocon’s agreement with Genentech establishes the earliest licensed launch periods for Pebrilzo in several major markets, creating a defined commercialisation pathway.

The company has also confirmed that product launches remain subject to obtaining the relevant regulatory approvals.

Pebrilzo Scheduled for European Launch in First Quarter of 2027

Under the global settlement, Biocon has secured the right to launch Pebrilzo in the European Union and United Kingdom during the first quarter of calendar year 2027, subject to regulatory authorisation.European markets represent an important destination for biosimilar medicines because healthcare systems increasingly use approved biosimilars to expand treatment options and manage expenditure on biological therapies.

Biosimilars are developed to be highly similar to approved reference biological medicines in quality, safety and efficacy. Their regulatory assessment involves extensive analytical comparisons and other evidence appropriate to the product.Pebrilzo’s planned European entry follows the positive opinion issued by the European Medicines Agency’s CHMP on September 21, 2026.

The committee recommended marketing authorisation for Pebrilzo as a 420 mg concentrate for solution for infusion for the treatment of HER2-positive breast cancer across multiple disease stages.The regulatory recommendation represents an important milestone in the product’s development and supports Biocon’s plans to introduce its pertuzumab biosimilar into European healthcare markets.

The CHMP opinion is a recommendation rather than the final marketing authorisation. Commercial launch requires completion of the applicable regulatory process.

United States Launch Planned for Third Quarter of 2028

Biocon’s agreement with Genentech establishes the third quarter of calendar year 2028 as the earliest licensed launch period for Pebrilzo in the United States.

The US market represents a significant commercial opportunity for manufacturers of biological medicines and biosimilars.Biological therapies are widely used in oncology and other specialist medical fields, with complex manufacturing processes contributing to substantial development and production costs.

Biosimilar competition can expand the range of treatment products available to healthcare providers and create opportunities for pharmaceutical companies with established biotechnology manufacturing capabilities.Biocon’s planned US launch will depend upon the applicable regulatory approval process administered by the US Food and Drug Administration.

The company has developed a broader international biosimilars business covering therapeutic areas such as oncology, immunology, diabetes and ophthalmology.The planned introduction of Pebrilzo would add another oncology product to its portfolio and expand its participation in the international market for monoclonal antibody therapies.

What Is Pertuzumab and How Does It Work?

Pertuzumab is a monoclonal antibody designed to target the human epidermal growth factor receptor 2, commonly known as HER2.

HER2 is a protein found on the surface of certain cells and is involved in signalling pathways associated with cell growth and division.In some breast cancers, tumour cells produce excessive quantities of HER2, a condition known as HER2 overexpression.

These cancers are classified as HER2-positive breast cancers and may require treatments specifically directed against the HER2 signalling pathway.Pertuzumab binds to HER2 and inhibits interactions involved in receptor signalling, helping interfere with processes that support the growth of HER2-positive tumour cells.

The medicine is used as part of specified treatment combinations rather than as a universal treatment for all forms of breast cancer.Its clinical use depends upon the patient’s diagnosis, disease stage, treatment history and applicable prescribing recommendations.

Biocon’s Pebrilzo is being developed to provide a biosimilar version of this established biological therapy.

Understanding Monoclonal Antibody Biotechnology

Monoclonal antibodies represent one of the most important classes of modern biological medicines.

These products are laboratory-produced proteins designed to recognise and bind to specific molecular targets.Unlike conventional small-molecule medicines, which are generally manufactured through chemical synthesis, monoclonal antibodies are typically produced using living cells maintained under carefully controlled manufacturing conditions.Their development requires sophisticated expertise in molecular biology, cell-line development, bioprocess engineering, purification, analytical testing and pharmaceutical formulation.

Manufacturers must maintain stringent controls over the production process because biological molecules are structurally complex and sensitive to changes in manufacturing conditions.The development of a biosimilar monoclonal antibody therefore involves considerably more than reproducing the chemical composition of a conventional medicine.

Biocon’s work on pertuzumab forms part of India’s expanding capabilities in advanced biological medicine development and manufacturing.The programme also demonstrates the increasing participation of Indian biotechnology enterprises in therapeutic fields traditionally dominated by large international pharmaceutical companies.

How Biosimilars Differ from Conventional Generic Medicines

Biosimilars and generic medicines both provide alternatives to existing pharmaceutical products, but their development and regulatory requirements differ considerably.A conventional generic medicine generally contains the same active pharmaceutical ingredient as its reference product and must demonstrate compliance with the relevant requirements for pharmaceutical equivalence and bioequivalence.

Biological medicines, including monoclonal antibodies, are considerably more complex. They consist of large molecules produced through biological manufacturing systems.Because living cells are involved in production, a biosimilar cannot be characterised simply as an identical chemical copy of the original medicine.

Instead, manufacturers must demonstrate that their biosimilar is highly similar to the approved reference product and has no clinically meaningful differences in safety, purity and potency.Regulatory evaluation involves extensive analytical characterisation, assessments of biological activity and other supporting evidence.

Biocon’s development of Pebrilzo illustrates the scientific and manufacturing capabilities required to participate in the international biosimilars industry.

European Regulatory Progress Supports Pebrilzo Development

Biocon achieved an important regulatory milestone on September 21, 2026, when it announced that the European Medicines Agency’s CHMP had issued a positive opinion recommending marketing authorisation for Pebrilzo.

The recommendation covered the 420 mg concentrate for solution for infusion formulation of the pertuzumab biosimilar.According to Biocon’s official announcement, the application was submitted by Biocon Biologics Ireland Limited, an indirect wholly owned subsidiary of Biocon Biologics Limited.

The company identified Pebrilzo as the first biosimilar to receive a positive CHMP opinion under the European Medicines Agency’s new tailored clinical development approach.

This regulatory development is significant because it reflects the evolving role of advanced analytical evidence in biosimilar assessment.Modern analytical technologies allow manufacturers and regulators to examine the structural and functional characteristics of complex biological molecules in considerable detail.Such assessments are central to demonstrating biosimilarity and establishing confidence in a proposed product.

The CHMP recommendation represents an important step towards European market authorisation, complementing the commercialisation framework subsequently established through Biocon’s patent settlement with Genentech.

European Medicines Agency Advances Tailored Biosimilar Development

The European Medicines Agency has been examining approaches that place greater emphasis on comprehensive analytical and functional characterisation during biosimilar development.

The evolving regulatory framework recognises that advances in analytical science can provide detailed evidence concerning the comparability of biological medicines.For monoclonal antibodies, this includes assessments of molecular structure, biological activity, product purity and other characteristics relevant to quality and clinical performance.

A tailored clinical development approach allows regulatory evidence requirements to reflect the characteristics of the biosimilar and the scientific understanding of its reference product.The objective is to maintain rigorous standards for safety and efficacy while avoiding unnecessary duplication of studies when sufficient scientific evidence is available through other methods.

Biocon’s September announcement identified Pebrilzo as an early beneficiary of this regulatory approach.The development demonstrates how advances in biotechnology, analytical science and regulatory evaluation can support the development of sophisticated biological medicines.

Biocon Secures Ten-Year Pertuzumab Supply Partnership in Brazil

Biocon’s international pertuzumab programme achieved another important milestone on September 8, 2026, when the company announced a partnership agreement with Bahiafarma and Bionovis in Brazil.

The agreement concerns the production and commercialisation of pertuzumab under Brazil’s Productive Development Partnership programme.According to Biocon’s official announcement, the consortium received 100% allocation under Brazil’s ten-year pertuzumab programme.

The arrangement provides access to Brazil’s public healthcare market for pertuzumab, which Biocon stated accounts for approximately 70% of the country’s demand for the medicine.The partnership also supports efforts to strengthen the availability of biological therapies within Brazil’s public oncology network.

Under the agreement, Biocon will receive milestone payments and a share of revenues generated through the partnership over the programme’s ten-year period.The arrangement establishes a long-term commercial framework for Biocon’s pertuzumab product in an important Latin American healthcare market.It also demonstrates the company’s strategy of combining advanced biotechnology development with partnerships tailored to the requirements of different national healthcare systems.

Brazil Partnership Supports International Biopharmaceutical Cooperation

Brazil’s Productive Development Partnership programme encourages cooperation among public healthcare institutions and pharmaceutical manufacturers to strengthen access to medicines and develop domestic production capabilities.

Biocon’s collaboration with Bahiafarma and Bionovis brings together an Indian biotechnology company and Brazilian healthcare and pharmaceutical organisations.The partnership covers pertuzumab, a specialised oncology medicine used in the treatment of HER2-positive breast cancer.

Long-term supply arrangements for biological medicines can contribute to healthcare planning by creating structured procurement and commercialisation frameworks.They can also support cooperation in pharmaceutical manufacturing, technology development and healthcare supply chains.

For Biocon, the agreement provides an opportunity to expand its international oncology business while participating in a government-supported healthcare programme.The Brazil partnership complements the company’s patent licensing arrangements for Europe, the United States and other markets, reflecting a geographically diversified approach to commercialising its pertuzumab biosimilar.

Patent Licensing Establishes a Framework for Global Market Entry

Patent settlements play an important role in the commercialisation of biosimilar medicines because biological therapies can be covered by multiple patents relating to their development, manufacturing or use.For biosimilar manufacturers, resolving patent disputes can provide greater certainty regarding the timing of permitted product launches.

Biocon’s settlement with Genentech establishes defined commercialisation periods across several major markets.The agreement permits a European Union and United Kingdom launch during the first quarter of 2027 and a United States launch during the third quarter of 2028.Other international markets are covered by arrangements allowing launches between 2026 and 2028, or earlier in certain circumstances.

These timelines provide Biocon with a framework for planning market access, commercial operations and international distribution.The settlement also demonstrates the importance of intellectual property management within the global biotechnology industry.

Successfully developing a biosimilar involves not only scientific research and manufacturing capabilities but also regulatory compliance, patent analysis and commercial planning.

Biocon’s latest agreement brings these elements together as the company advances Pebrilzo towards international markets.

Oncology Biosimilars Can Expand Access to Biological Therapies

Biological medicines have transformed the treatment of several diseases, including certain cancers, autoimmune disorders and chronic inflammatory conditions.Monoclonal antibodies are particularly important in oncology because they can target molecular characteristics associated with tumour development.

However, the complex manufacturing processes involved in producing biological medicines contribute to their high development and production costs.The introduction of approved biosimilars can increase competition and provide healthcare systems with additional treatment options.

Greater competition may create opportunities for more sustainable procurement and broader patient access, depending on market conditions and healthcare policies.In the case of pertuzumab, biosimilar availability could offer additional choices for healthcare providers treating eligible patients with HER2-positive breast cancer.

Regulatory authorities require biosimilars to meet applicable standards of quality, safety and efficacy before they can be marketed.Biocon’s Pebrilzo programme contributes to the development of this market by expanding the number of companies capable of manufacturing sophisticated oncology biological medicines.

India’s Biotechnology Industry Expands into Advanced Cancer Medicines

India has established an extensive pharmaceutical manufacturing industry and is increasingly developing capabilities in advanced biological medicines.

Biosimilars represent an important area of this expansion because their development requires expertise in biotechnology, cell culture, protein engineering, pharmaceutical manufacturing and analytical science.The production of monoclonal antibodies also depends upon highly specialised manufacturing facilities and quality-control systems.

Indian pharmaceutical companies participating in the biosimilars industry are developing capabilities that extend beyond traditional generic medicines.

Biocon has established an international biosimilars business spanning multiple therapeutic areas, including oncology, immunology, diabetes and ophthalmology.The company’s work on pertuzumab demonstrates the growing sophistication of India’s biopharmaceutical industry.

Participation in international markets also requires compliance with demanding regulatory standards established by authorities such as the European Medicines Agency and the US Food and Drug Administration.Progress in these markets can strengthen the international standing of Indian biotechnology manufacturers and encourage further investment in research, development and advanced production infrastructure.

Biocon Strengthens Its International Oncology Portfolio

Pebrilzo forms part of Biocon’s broader strategy to develop and commercialise biosimilar medicines across major therapeutic categories.

The company has invested in biological medicine development, manufacturing capabilities and international commercial operations.Its oncology portfolio includes biosimilar products intended to support treatment across different cancer indications.

The addition of pertuzumab expands the company’s participation in the market for HER2-targeted therapies.The global patent settlement provides greater clarity regarding future launch periods, while the European regulatory recommendation represents progress towards market authorisation.

The Brazil partnership adds a long-term supply and commercialisation arrangement in Latin America.Together, these developments create a framework for introducing Pebrilzo across different international healthcare systems.

They also demonstrate the combination of scientific development, regulatory engagement and commercial partnerships required to bring complex biological medicines to market.

Pebrilzo Development Highlights India’s Growing Capabilities in Monoclonal Antibodies

The development of a monoclonal antibody biosimilar involves sophisticated scientific and manufacturing processes.

Researchers must characterise the reference biological medicine and develop a product with highly similar structural and functional properties.

Manufacturing requires appropriate cell lines, controlled biological production processes, purification systems and extensive testing.Maintaining consistent product quality across manufacturing batches is particularly important because biological medicines are sensitive to variations in production conditions.

Regulatory authorities evaluate these characteristics to establish confidence in the biosimilar’s quality and performance.Biocon’s progress with Pebrilzo reflects the capabilities that Indian biotechnology companies are building in advanced pharmaceutical development.

Such expertise can support future work involving other monoclonal antibodies and complex biological medicines.The growing availability of specialised scientific personnel, research infrastructure and biopharmaceutical manufacturing facilities provides a foundation for further expansion of India’s biotechnology sector.

Biocon Advances Global Commercialisation of Pebrilzo

Biocon’s October 14, 2026, patent settlement with Genentech represents an important milestone in the international development of its pertuzumab biosimilar, Pebrilzo.

The agreement establishes licensed launch periods in the European Union, United Kingdom, United States and other international markets while resolving pending patent disputes between the companies.The development follows the European Medicines Agency’s positive CHMP opinion in September and Biocon’s ten-year pertuzumab supply partnership in Brazil.

These achievements demonstrate the company’s progress across three essential aspects of biopharmaceutical commercialisation: scientific and regulatory development, intellectual property arrangements and international market access.

Pebrilzo’s planned introduction into overseas markets will expand Biocon’s oncology biosimilars portfolio and create additional opportunities to participate in the global market for advanced biological medicines.The programme also highlights the increasing capabilities of India’s biotechnology industry in developing complex monoclonal antibody products for international healthcare markets.

Through continued investment in biosimilar research, manufacturing and global partnerships, Biocon is strengthening India’s participation in advanced pharmaceutical innovation and the international supply of biological therapies.

---

References

1. Biocon Limited — Official Company Statement and Stock Exchange Disclosure

Date: October 14, 2026

Title: Biocon Secures Earliest Licensed Launch Dates for Pebrilzo® (bPertuzumab) Following Global Patent Settlement with Genentech

Details: Global patent settlement, resolution of disputes with Genentech, and permitted launch timelines for the European Union, United Kingdom, United States and other markets.

https://www.biocon.com/biocon-secures-earliest-licensed-launch-dates-for-pebrilzo-bpertuzumab-following-global-patent-settlement-with-genentech

2. Biocon Biologics — Official Company Statement

Date: October 14, 2026

Title: Biocon Secures Earliest Licensed Launch Dates for Pebrilzo® Following Global Patent Settlement with Genentech

Details: Confirmation of the settlement, pertuzumab’s HER2-targeting mechanism and licensing arrangements for international markets.

https://www.bioconbiologics.com/biocon-secures-earliest-licensed-launch-dates-for-pebrilzo-bpertuzumab-following-global-patent-settlement-with-genentech

3. Biocon Limited — Official Press Release

Date: September 21, 2026

Title: Biocon’s Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach

Details: Positive CHMP opinion for Pebrilzo, proposed European marketing authorisation and regulatory development of the pertuzumab biosimilar.

https://www.biocon.com/biocons-pertuzumab-becomes-first-biosimilar-to-secure-ema-chmp-approval-recommendation-under-new-tailored-clinical-approach

4. Biocon Limited — Official Press Release

Date: September 8, 2026

Title: Biocon Secures 10-Year Supply Contract for Pertuzumab in Brazil

Details: Partnership with Bahiafarma and Bionovis under Brazil’s Productive Development Partnership programme and long-term commercial arrangements for pertuzumab.

https://www.biocon.com/biocon-secures-10-year-supply-contract-for-pertuzumab-in-brazil

5. Biocon Limited — Stock Exchange Disclosures

Official repository of company statements and regulatory announcements submitted to Indian stock exchanges.

https://www.biocon.com/investor-relations/stock-exchange-disclosures/company-statement

6. European Medicines Agency

Official information concerning biosimilar medicines, their scientific assessment and European marketing authorisation procedures.

https://www.ema.europa.eu/en/human-regulatory-overview/biosimilar-medicines-overview

7. U.S. Food and Drug Administration

Official information concerning biosimilar biological medicines, regulatory requirements and the evaluation of biosimilarity.

https://www.fda.gov/drugs/biosimilars

8. Biocon Biologics Limited

Official company information concerning global biosimilar development, manufacturing and commercial operations.

https://www.bioconbiologics.com

---